Succesful asthma control is still limited in clinical practice, despite the availability of effective treatments. Many patients rely on their short activing bronchodilator for the management of their asthma because of the immediate effects, rather…
ID
Bron
Verkorte titel
Aandoening
Asthma; SABA overuse; opinions SABA use;
Astma; overmatig gebruik SABA; meningen SABA use;
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
This project will result in the PCAMQ.
Achtergrond van het onderzoek
This study aims to develop the Patient-Centered Asthma Management Questionnaire (PCAMQ), which measures patients’ reliever and controller medication and their beliefs regarding asthma medication. To this end, two focus groups and two interviews will be conducted in several countries (Netherlands,Canada, Spain, France, UK). Eventually, resulting the PCAMQ.
Doel van het onderzoek
Succesful asthma control is still limited in clinical practice, despite the availability of effective treatments. Many patients rely on their short activing bronchodilator for the management of their asthma because of the immediate effects, rather than the treatment of the underlying inflammation by inhaled corticosteroids. The persistance of unbalanced reliever- and controller medication use indicates that other solutions besides advocating guideline-based treatment are required.
Onderzoeksopzet
2 focusgroups(6-8 participants) and 2 interviews(2 participants) will be conducted. Each will be performed in several countries (Netherlands,Canada, Spain, France, UK).
Onderzoeksproduct en/of interventie
The objective of the Patient-Centred Asthma Management Questionnaire (PCAMQ) project is to develop the PCAMQ which measures patients’ use of reliever- and controller medication and their beliefs and perception regarding asthma and its treatment. To this end, two focusgroups(6-8 participants) and interviews (2 participants) will be conducted in several countries (Netherlands,Canada, Spain, France, UK).
Publiek
University Medical Center Groningen<br>
Antonius Deusinglaan 1
J.W.H. Kocks
Groningen 9713 AV
The Netherlands
+31 (0)50 3632971
j.w.h.kocks@med.umcg.nl
Wetenschappelijk
University Medical Center Groningen<br>
Antonius Deusinglaan 1
J.W.H. Kocks
Groningen 9713 AV
The Netherlands
+31 (0)50 3632971
j.w.h.kocks@med.umcg.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1) Patients with mild asthma aged 18 years and older; 2) Being prescribed inhalation medication; reliever and controller; 3) Adequate oral fluency in the relevant language to enable participation in the focus group or interview; 4)Willing and able to provide written informed consent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1) (co-)Diagnosis of COPD, emphysema, chronic bronchitis or any other chronic respiratory disease (e.g., bronchiectasis); 2) Use of combination inhalers (ICS + LABA in one inhaler); 3) Single maintenance and reliever therapy (SMART); 4)Documented dementia or other mental impairment such that they are unable to provide informed consent or to complete the required tasks.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL6969 |
| NTR-old | NTR7157 |
| Ander register | : 201700403 UMCG |